Eisai announced the availability of Fycompa (perampanel) Oral Suspension for use in patients who have difficulty swallowing tablets or prefer liquids. The oral suspension, which was recently approved, is a bioequivalent interchangeable alternative to Fycompa tablets.
Fycompa is indicated as adjunctive therapy for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures, and primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy ≥12 years old. It is a non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist. The precise mechanism by which it exerts antiepileptic effects in humans has not been fully elucidated.
Fycompa is a CIII controlled substance already available as 2mg, 4mg, 6mg, 8mg, 10mg, and 12mg strength tablets. The new oral suspension formulation is now available as a 0.5mg/mL strength in 340mL bottles with an adapter and syringes.
For more information call (888) 274-2378 or visit Fycompa.com.